Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Result of General Meeting and Issue of Equity

RNS Number : 0602Y
Redx Pharma plc
28 February 2017
 

28 February 2017

REDX PHARMA PLC

("Redx" or "the Company")

 

Result of General Meeting and Issue of Equity

 

 

Redx, the drug discovery and development company, is pleased to announce that, at a General Meeting held earlier today, all the resolutions proposed, as set out in the Notice of General Meeting circulated to shareholders on 10 February 2017, were duly passed.

 

As a result 26,779,958 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") will be admitted to trading on 1 March 2017.

 

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue. Following admission of the New Ordinary Shares on 1 March, the Company's total issued share capital will comprise 126,477,914 Ordinary Shares. This number may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

For further information, please contact:

 

Redx Pharma Plc


Neil Murray, Chief Executive

T: +44 1625 469 900 

Karl Hård, Head of Investor Relations &

Corporate Communications

T: +44 7491 651 406

 

Cantor Fitzgerald Europe (Nomad & Joint Broker)

 

T: +44 20 7894 7000

Phil Davies / Michael Reynolds


 

WG Partners LLP (Joint Broker)

 

T: +44 20 3705 9330

Claes Spång / Chris Lee / David Wilson


 

 

About Redx Pharma Plc

Company website: redxpharma.com

 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCTPMMTMBJTBIR



Redx Pharma Plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use